At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.

We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. 

Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. 

Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.

Health Care

Life Sciences

Therapeutics

Alumis

Martin Babler

Tori Lovell

Alexis Brayton

Melissa Ceo

Grace Halteh

Director, Regulatory Strategy

Lily Gong

Jennifer Cortes

Kolbot By

Tim Owens

Derrick Richardson

Alan Colowick

Roy Hardiman

Mark Bradley

Jörn Drappa

John Schroer

David M Goldstein

Leadership Team

Clinical and Development Operations

Research and Development

Clinical and Scientific Research Team

Human Resources and Talent Acquisition

Regulatory and Legal

Teams at Alumis